Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.63 |
| ▸ | GABRD | O14764 | 2/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.63 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.63 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.63 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.63 |
| ▸ | GABRE | P78334 | 2/20 | 0.63 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.63 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.63 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.63 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801314 | 0.83 | CSNK2A2 (0.56) | CYP1A1CYP1A2CYP1B1MAOBCYP3A4 | |
| SCHEMBL21801178 | 0.82 | CYP1A1 (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21801158 | 0.81 | CYP1A2 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30744123 | 0.80 | CYP1A1 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21801307 | 0.80 | CYP1A1 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4990151 | 0.77 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL26680095 | 0.77 | MAOB (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30000774 | 0.76 | MAOB (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21801086 | 0.74 | CYP1A1 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4649432 | 0.74 | CSNK2A2 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112601743-B | Flavone compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3849966-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112601743-A | Flavone compounds for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | PCNA, DNMT1, DNMT3B | GABRP 3681/4885GABRD 3647/4885GABRA1 4071/4885 |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | PCNA, DNMT1, DNMT3B | GABRP 3681/4885GABRD 3647/4885GABRA1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.